Action AMLX AMYLYX PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Amylyx Pharmaceuticals, Inc.

Actions

AMLX

US03237H1014

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
2,36 USD +9,26 % Graphique intraday de Amylyx Pharmaceuticals, Inc. +43,03 % -83,97 %
10/07 Transcript : Amylyx Pharmaceuticals, Inc. - Special Call
10/07 Amylyx Pharmaceuticals acquiert l'avexitide d'Eiger BioPharmaceuticals pour 35 millions de dollars MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist with FDA Breakthrough Therapy Designation
AQ
Amylyx Pharmaceuticals : Avexitide Acquisition Conference Call Presentation
PU
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
BU
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
BU
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
BU
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
BU
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
BU
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
BU
The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX
PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
BU
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
BU
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders
PR
AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX
BU
AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO, ALBRIOZA from the Market, Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
AQ
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX
PR
AMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX
PR
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AMLX
  4. Actualités Amylyx Pharmaceuticals, Inc.
  5. Communiqués